ES2069014T3 - 11-acilprostaglandinas que reducen la presion intraocular. - Google Patents

11-acilprostaglandinas que reducen la presion intraocular.

Info

Publication number
ES2069014T3
ES2069014T3 ES90308268T ES90308268T ES2069014T3 ES 2069014 T3 ES2069014 T3 ES 2069014T3 ES 90308268 T ES90308268 T ES 90308268T ES 90308268 T ES90308268 T ES 90308268T ES 2069014 T3 ES2069014 T3 ES 2069014T3
Authority
ES
Spain
Prior art keywords
acilprostaglandinas
intraocular pressure
compound
carbon atoms
reduce intraocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90308268T
Other languages
English (en)
Inventor
Ming Fai Chan
David Frederick Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2069014T3 publication Critical patent/ES2069014T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL INVENTO SE REFIERE AL USO DE UN COMPUESTO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO PARA LA HIPERTENSION INTRAOCULAR, DICHO COMPUESTO POSEE LA FORMULA (I): EN DONDE LOS GRUPOS HIDROXIL ESTAN TANTO EN LA CONFIGURACION ALFA COMO BETA; LOS ENLACES PUNTEADOS EN C-5, C-13 Y C-17 REPRESENTAN TANTO UN ENLACE SIMPLE COMO UN ENLACE DOBLE QUE PUEDE PRESENTARSE EN LA CONFIGURACION CIS O TRANS; A ES -OH, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA O -OR1, DONDE R1 ES ALKIL DE ENTRE 1 Y 6 ATOMOS DE CARBONO; R ES UN HIDROCARBONO ACICLICO, SATURADO O INSATURADO, TENIENDO DE ENTRE 1 Y 20 ATOMOS DE CARBONO, O R ES -(CH2)NR2 DONDE N VALE ENTRE 0 Y 10 Y R2 ES UN ANILLO ALIFATICO O UNA ANILLO AROMATICO O HETEROAROMATICO.
ES90308268T 1989-07-27 1990-07-27 11-acilprostaglandinas que reducen la presion intraocular. Expired - Lifetime ES2069014T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38683589A 1989-07-27 1989-07-27

Publications (1)

Publication Number Publication Date
ES2069014T3 true ES2069014T3 (es) 1995-05-01

Family

ID=23527257

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90308268T Expired - Lifetime ES2069014T3 (es) 1989-07-27 1990-07-27 11-acilprostaglandinas que reducen la presion intraocular.

Country Status (10)

Country Link
US (1) US5446041A (es)
EP (1) EP0410785B1 (es)
JP (1) JP3020260B2 (es)
AT (1) ATE119776T1 (es)
AU (1) AU635293B2 (es)
CA (1) CA2021316C (es)
DE (1) DE69017786T2 (es)
DK (1) DK0410785T3 (es)
ES (1) ES2069014T3 (es)
IE (1) IE67172B1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312842A (en) * 1992-10-30 1994-05-17 Allergan, Inc. Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives
US5476872A (en) * 1993-10-18 1995-12-19 Allergan, Inc. 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1998021180A1 (en) 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
ES2170956T3 (es) * 1996-05-28 2002-08-16 Allergan Sales Inc Derivados 2-alquenilicos de acido ciclopentan(en)oico como agentes terapeuticos en el tratamiento de hipertension ocular.
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
US6248783B1 (en) 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6291522B1 (en) 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US6376533B1 (en) 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6586462B2 (en) 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6531504B2 (en) 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US6476064B1 (en) 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US7872045B2 (en) * 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
WO2003040126A1 (en) * 2001-11-05 2003-05-15 Allergan, Inc. φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US6977260B2 (en) 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2004108215A1 (en) * 2003-06-06 2004-12-16 Allergan, Inc. Piperidinyl prostaglandin e analogs
US7326716B2 (en) * 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
US7015243B2 (en) * 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7235586B2 (en) * 2003-09-09 2007-06-26 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CA2571782C (en) * 2004-07-02 2012-07-03 Allergan, Inc. Prostaglandin analogs
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU2009239372B2 (en) * 2008-04-24 2013-09-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
ES2805880T3 (es) 2013-10-31 2021-02-15 Allergan Inc Implantes intraoculares que contienen prostamida y métodos de uso de éstos
BR112018005589A2 (pt) 2015-09-22 2018-10-09 Graybug Vision Inc “composto, composição farmaceuticamente aceitável, e, uso de um composto”

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001306A (en) * 1971-12-30 1977-01-04 The Upjohn Company Prostaglandin F.sub.α 15-monoacrylates
DE2357781A1 (de) * 1972-11-28 1974-05-30 Ciba Geigy Ag Neue 15-substituierte prostansaeurederivate und verfahren zu deren herstellung
US4060540A (en) * 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
EP0172963A1 (en) * 1984-08-30 1986-03-05 Ono Pharmaceutical Co., Ltd. Prostaglandin analogues, processes for their preparation and compositions containing them
US4883819A (en) * 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
ZA88963B (en) * 1987-02-27 1989-11-29 Allergan Inc Prostaglandins useful for lowering intraocular pressure
ES2042625T5 (es) * 1987-04-03 2000-07-16 Univ Columbia Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
SE8703854D0 (sv) * 1987-10-07 1987-10-07 Pharmacia Ab Prostaglandinderivat for behandling av glaukom eller okuler hypertension

Also Published As

Publication number Publication date
ATE119776T1 (de) 1995-04-15
CA2021316A1 (en) 1991-01-28
EP0410785B1 (en) 1995-03-15
IE67172B1 (en) 1996-03-06
DE69017786T2 (de) 1995-08-03
CA2021316C (en) 2000-10-24
DE69017786D1 (de) 1995-04-20
AU635293B2 (en) 1993-03-18
AU5978690A (en) 1991-01-31
US5446041A (en) 1995-08-29
JP3020260B2 (ja) 2000-03-15
JPH0358931A (ja) 1991-03-14
EP0410785A2 (en) 1991-01-30
IE902721A1 (en) 1991-02-27
DK0410785T3 (da) 1995-06-19
EP0410785A3 (en) 1991-12-27

Similar Documents

Publication Publication Date Title
ES2069014T3 (es) 11-acilprostaglandinas que reducen la presion intraocular.
LU91541I2 (fr) latanoprost et ses dérivés pharmaceutiquement acceptables (XALATAN)
KR960007545A (ko) 합성 흥분성 아미노산
KR910002448A (ko) 안내압을 저하시키는 11,15-디아실 프로스타글란딘
LU92509I2 (fr) Travoprost et ses dérivés pharmaceutiquement acceptables (TRAVATAN)
AR018033A1 (es) Analogos 13-oxa prostaglandinas, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
DE69129921T2 (de) Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten
MY102565A (en) Novel derivatives of guanine
KR890006241A (ko) 설사약
ES530708A0 (es) Un procedimiento para la preparacion de nuevos derivados de furanona
HU9203920D0 (en) Pfg 1 alcohols and their application for reducing pressure in eyes
KR910016660A (ko) 스쿠알렌 에폭시다제 억제제로서의 스쿠알렌의 디-및 테트라-플루오르 유사체
KR910019621A (ko) 상승병용을 이용한 안고혈압 치료
DE3750464D1 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
ES2084006T3 (es) Uso de 2-cicloalquil-amino-oxazolinas para reducir o mantener la presion intraocular.
EP0399839A3 (en) Intraocular pressure reducing 15-acyl prostaglandins
KR910019622A (ko) 안과용 상승적 병용으로 안고혈압의 치료
KR920003972A (ko) 프로스타시클린 화합물을 이용한 백내장 치료
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)
ATE289817T1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
KR950032113A (ko) 프로스타글란딘 에프 에스테르
KR890003372A (ko) 피리미도[2,1-b] 벤조티아졸 유도체로된 동맥경화 치료의약
KR940007010A (ko) 옥사졸리딘

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 410785

Country of ref document: ES